血清CD147水平在卵巢癌中的诊断价值及对预后复发的影响

Diagnostic value of serum CD147 level in ovarian cancer and its effect on prognosis and recurrence

摘要:

目的：探讨血清细胞外基质金属蛋白诱导子（CD147）在卵巢癌中的诊断价值及对预后和复发的影响。方法：收集110例卵巢癌患者、60例卵巢良性疾病患者及50例健康体检者，ELSIA检测血清CD147水平，比较各组中的差异，比较与CA125、人附睾蛋白4（HE4）之间的差异，分析与不同临床病程、病理特征、病理分级、临床分期、复发率和无进展生存时间（progression-free survival，PFS）之间的相关性。结果：卵巢癌患者组血清CD147水平[（137.61±86.06） pg/mL]高于良性疾病组和健康体检组；CD147的灵敏度、特异度和AUC（72.3%、93.8%、0.882）与CA125、HE4相当，差异均无统计学意义（P>0.05）；CD147、CA125、HE4术后化疗6个疗程后水平明显低于术前水平（P＞0.05），且三者在术前、术后化疗6个疗程后均呈显著正相关（r=0.321，r=0.415，P<0.01）；术前和术后化疗6个疗程后，CD147水平在卵巢癌患者不同年龄、肿块大小、是否绝经、产次、组织分型、初潮时间中均无统计学差异（P＞0.05），在不同FIGO分期、病理分级、浸润程度、淋巴是否转移和转移灶个数上存在统计学差异（P<0.05）；化疗6个疗程结束后血清CD147水平与复发率和PFS呈显著性相关（χ2=22.275，log-rank=20.400，P<0.01）。结论：血清CD147对卵巢癌诊断具有一定意义，其表达水平的变化与肿瘤的恶性程度、浸润、转移、预后和复发有密切联系，动态观察血清CD147表达水平的变化可作为卵巢癌诊断、手术方法选择、疗效评价及预后监测的参考指标。

Abstract:

Objective：To investigate the diagnostic value of serum extracellular matrix metalloprotein inductor（CD147） in ovarian cancer and its effect on prognosis and recurrence. Methods：A total of 110 ovarian cancer patients，60 ovarian benign diseases patients and 50 healthy people were collected. Levels of serum CD147 were tested by ELSIA，and were compared among three groups；Serum CD147，CA125 and HE4 were compared；correlation of serum CD147 with clinical course，histology，pathologic stage，clinical stage，recurrence rate and progression-free survival（PFS） was analyzed. Results：The level of serum CD147[（137.61±86.06） pg/mL] in the ovarian cancer group was higher than that in the benign disease group and the healthy group. The sensitivity，specificity and AUC of serum CD147（72.3%，93.8% and 0.882） were similar to those of CA125 and HE4，without significantly statistical differences（P>0.05）. Levels of serum CD147，CA125 and HE4 after six chemotherapy courses were significantly lower than those before the therapy （P>0.05），and showed significant positive correlation both before and after six chemotherapy courses（r=0.321，r=0.415，P<0.01）. Levels of serum CD147 before and after six chemotherapy courses had no statistical difference in age，tumor size，menopausal status，production time，histological type，menophania age of ovarian cancer patients（P>0.05），but had significant differences in FIGO staging，pathologic stage，infiltration，lymphatic metastasisand numbers of metastases（P<0.05）. Levels of serum CD147 before therapy and after six chemotherapy courses were significantly correlated with recurrence rate and progression-free survival（χ2=22.275，log-rank=20.400，P<0.01）. Conclusion：The serum CD147 has certain significance for diagnosing ovarian cancer and its expression level is closely related to the malignancy degree，invasion，metastasis，prognosis and recurrence of the tumor. Dynamic observation of the expression level of serum CD147 can be a reference index for diagnosing ovarian cancer，selecting surgical methods，evalu－ating therapeutic efficiency and monitoring prognosis.